Loading ...
Sorry, an error occurred while loading the content.

Fw: NATAP/EASL: CPG 10101-New HCV Toll Receptor Antagonist

Expand Messages
  • Alley Pat
    NATAP http://natap.org/ ... New HCV Drug CPG 10101, a Toll Receptor Antagonist EASL 41st Meeting of the European Association for the Study of Liver Diseases
    Message 1 of 1 , May 9 7:15 PM
    • 0 Attachment
      NATAP http://natap.org/
      _______________________________________________



      --------------------------------------------------------------------------------


      New HCV Drug CPG 10101, a Toll Receptor Antagonist

      EASL
      41st Meeting of the European Association for the Study of Liver Diseases
      April 26-30, 2006
      Vienna, Austria
      Â
      Â
      â?¢ Early Viral Response to New HCV Drug CPG 10101 Toll-Receptor Antagonist, in Combination with Pegylated Interferon and/or Ribavirin, in Chronic HCV Genotype 1 Infected Patients with Prior Relapse Response - (05/09/06)
      Â
      â?¢ Randomized, Placebo-Controlled, Dose-Escalation Trial of New HCV Drug CPG 10101 Toll-Receptor Antagonist in Patients with Chronic Hepatitis C Virus - (05/09/06)





      --------------------------------------------------------------------------------


      _______________________________________________
      NATAP nataphcv mailing list -- nataphcv@...

      This is an annoucement-only mailing list. Do not reply.

      To unsubscribe: send a blank email to nataphcv-request@... with a subject of unsubscribe.


      For more information, see http://seven.pairlist.net/mailman/listinfo/nataphcv

      _______________________________________________


      [Non-text portions of this message have been removed]
    Your message has been successfully submitted and would be delivered to recipients shortly.